Hormonal
Growth hormone (GH) replacement therapy in adults with growth hormone deficiency (GHD) improves non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) by reducing visceral adipose tissue and directly decreasing hepatic lipogenesis.
If you have been diagnosed with adult Growth Hormone Deficiency, treating it with GH replacement therapy can significantly improve liver health, including reducing fatty liver and inflammation. This is not just about weight loss; GH has a direct effect on liver cells to reduce fat production. Consult an endocrinologist to see if you qualify for this therapy, especially if you have NAFLD or NASH.
GH profoundly reduces visceral fat, which plays an important role in the development of NAFLD. Furthermore, GH directly reduces lipogenesis in the hepatocytes.
Why this rating
The paper is a review citing multiple human studies (some retrospective, some case-controlled) and animal models, but notes conflicting results in some smaller studies.
Source
The Role of Growth Hormone and Insulin-Like Growth Factor-I in the Liver
Yutaka Takahashi · International Journal of Molecular Sciences · 2017
DOI 10.3390/ijms18071447
More from this paper
- Low serum levels of IGF-I are associated with the severity of NAFLD, including inflammation, hepatocyte ballooning, and fibrosis, even in non-GHD patients.Good
- Insulin-like Growth Factor-I (IGF-I) administration ameliorates liver fibrosis and NASH by inducing cellular senescence in hepatic stellate cells (HSCs), thereby inactivating them and limiting fibrosis progression.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →